Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Day (June 2023)
42 slides from Windtree Therapeutics's investor day presentation, Jun 14, 2023
Slide 1: Windtree Therapeutics R&D and Investor Day
Windtree Therapeutics ‘ R&D and Investor Day June 14, 2023 Se —@ WINDTREE (NASDAQ: WINT)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the ‘Company
Slide 3: Welcome and Agenda
Welcome Craig Fraser, President &CEO Agenda Steve Simonson, MD * Introduce Windtree John Teerlink, MD * Overview the Cardiogenic Shock Market and Landscape * Introduce Istaroxime and the Rationale for a Cardiogeni¢ Shock Program + SEISMIC Trial and Results * Development Strategy and Plans to Transit
Slide 4: Windtree Therapeutics overview
q Icy ee ~~ WINDTREE THERAPEUTICS Biopharmaceutical company with advanced clinical focus on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has consistently demonstrate
Slide 5: Pipeline
Pipeline Lead Products | Indication Istaroxime Cardiogenic Shock Istaroxime Acute Heart Failure OralSERCA2a Chronic Heart Failure, including Activators potentially HFPEF ‘Treatment Resistant Rostafuroxin Hypertension - Genetically Associated KL4surfactant KL4sufactant OrvgDevice Tx for RDS and poten
Slide 6: Istaroxime Cardiogenic Shock
2 - my Istaroxime Cardiogenic Shock Potential indication in active clinical development
Slide 7: Cardiogenic Shock
Cardiogenic Shock A severe presentation of heart failure characterized by very low blood pressure and flow to and from the body and vital organs (hypoperfusion) accompanied by high filling pressures of the heart and decreased urine output. Itis a treatment emergency. » Caused by severe impairment of
Slide 8: Market Research: Early Cardiogenic Shock Treatment
Market Reseai Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need + No satisfactory pharmacological intervention to reverse the conditions ~ Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal
Slide 9: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action @ wees ene Relaxation ‘and subsequent contraction cycle via stimulation of SERCAZa activity which enhances calcium reuptake @ Incr
Slide 10: Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials
Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials Cardiac Function Improved * Significant increase in stroke volume (amount of blood pumped with each heartbeat) + Lowered cardiac filling pressures art Dose-related Increase in Systolic Blood Pressure ~ i te eS Maintain or Inc
Slide 11: SEISMiC Early Cardiogenic Shock Study
SEISMiC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure @ p 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization to placebo or istaroxime.
Slide 12: Difference in SBP Profile
NE Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population 0, Distaroxime Placebo Change from Baseline in SBP (mmH 8 7 6 5 4 3 1 ° o os 1 is 2 2 3 38 4 45 5 SS 6 Se Hours from Infusion Inititation _ WINDTREE [xe
Slide 13: Secondary Results
\ Secondary Results — Results Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure ‘mITT Population 20 Pr ~®Istaroxime 3 © Placebo z = & ra a A 6 | p=0.025 for AUC alAbed ° 0 2 24 Hours from Infusion Initiation ve WINDTREE 3)
Slide 14: Cardiac Function Improvement
Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: v Cardiac index significantly increased yv Stroke volume substantially increased » (4 mL/m2) approaching statistical significance y Other parameters were also im
Slide 15: Treatment was Associated with a Favorable Renal Profile
Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients Estimated Glomerular Filtration Rate miTT Population a 22 = —E o g = £2 4 resale ' ~. 2a £4 Pec a= 5 ee lair | ie o 6 © Placebo 2 ° 2 24 36 ms eo 7 a % Hours from infusion initiati
Slide 16: Comparison of Doses
) Comparison of Doses of Doses 1.0 yg/kg/min Produced a Favorable Effect on SBP 1.0 ug/kgimin dosing was associated with: * Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function » More favorable adverse event, serious adverse event and clinical event pro
Slide 17: SEISMIC Results Summary
SEISMIC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) - SBP increases were rapi
Slide 18: Cardiogenic Shock Development Strategy
Cardiogenic Shock Development Strategy SEISMIC Extension Study = Extended and titrated dosing for optimization = Additional characterization SEISMIC a” arses see nase 3* Study * Position for EOP2 * Proof of concept > srailes sepreties by SGA! Stake Bde’ to/AUE AHF safety data base, = Learnings about
Slide 19: Plan For Dose Optimization — Extension Study
Plan For Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associa
Slide 20: Descriptors of SCAI Shock Stages
Descriptors of SCAI Shock Stages: e> z Basing cS nics WINDTREE
Slide 21: SCAI Stage C Study
SCAI Stage C Study linatt loll, se a6 WINDTREE Study Objectives: * 20 patients with SCAI Stage C shock due to ADHF: Hypotension + hypoperfusion Protocol will allow additional enrollment after this review Istaroxime or placebo will be added to initial standard of care shock therapy (blinded) * Hold s
Slide 22: Our Development Plan (studying SCAI stage B, C)
Our Development Plan (studying SCAI stage B, C) Designed To Maximize Cardiogenic Shock Addressable Market % of CS Patients, Experiencing Early to Extreme CS, 2% ‘Very severe and unstable: mechanical intervention 1% —_______+ 30% KS SCAI B, C: Focus for Ista CS Development 86% + SCAICcharacterized by
Slide 23: Cardiogenic Shock Opportunity
Cardiogenic Shock Opportunity <4 NIN WSN se a6 WINDTREE Average length of stay in U.S. ~19.5 days: >$200k in patient costs OPPORTUNITY DRIVERS Currently available pharmacologictreatments have undesirable side effects and poor outcomes Very high cost of cardiogenicshock treatment creates opportunity
Slide 24: John R. Teerlink, MD
se a6 WINDTREE John R. Teerlink, MD Harvard Medical School followed by an internal medicine residency at the University of California San Francisco (UCSF). He continued a post-doctoral research fellowship at Hoffman-LaRoche in Basel, Switzerland. Dr. Teerlink completed his cardiovascular medicine fe
Slide 25: Heart Failure — Large, Growing Market But Underserved
Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing #1 cause of U.S. Annual Admissions Patients hospitalization ~1.3M us. Tus. ; in patients ~1.5M cv. 25M +F worawiae > 65 years old >$18B 0 In-patient mortality annual U.S. hospit
Slide 26: Istaroxime AHF Phase 2a & 2b Studies
Istaroxime AHF Phase 2a & 2b Studies se a6 WINDTREE ZS eh oO Phase 2a n=120 Dosing= 6 hour ADHF Patients 0.5, 1, 1.5 ygikgimin Infusion Phase n=120 Dosing= 24 hour ADHF Patients 0.5, 1.0 uokaimin Infusion 2b (ayspnea plusneed {orlv furosemide 2 40mg) Primary: PCWP significantly improved Stroke Vol &
Slide 27: Istaroxime — Acute Heart Failure
i Istaroxime — Acute Heart Failure Objective: Evaluate potential Phase 3 AHF program based on data from our cardiogenic shock program Potential Phase 3 AHF Program Augment our data from the positive phase 2a and phase 2b AHF studies ay with the efficacy, safety and dosing and characterization learni
Slide 28: Next Generation, Oral SERCA2a Activators
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a & Na+/K+) Activators Compounds * Oral & i.v. therapies for chronic “Next generation istaroxime” as
Slide 29: Active Engagement in Out-License and Partnership Opportunities
Active Engagement in Out-License and Partnership Opportunities v AEROSURF / KL4 Platform — Exclusive global license to Lee’s Pharm (SEHK:950) and Zhaoke. Potential proceeds: © Up to $78.9 million in potential milestone payments Global / Regional © Low double-digit % royalties Licensing © WINT no lon
Slide 30: Strategy for Value-Creation
Strategy for Value-Creation - Focus for the Next 4-6 Quarters Clinical Milestones Strong trial Extension and Enable transi Execute sel . WINDTREE Transformative BD THERAPEUTICS ; Licensing and partnership for High IR/PR non-dilutive value Communication Y ‘dedicated media, et opportunities and mitiga
Slide 31: Financial Summary & Capitalization
Financial Summary & Capitalization Cash March 31, 2023 $4.2M Driving Capital Efficiency to Program Investment Significantly reduced company expenses and cash burn via out- March 31, 2023 Pro Forma $15.0M licensing KL4 platform, focused resources on lead priority program Common Equivalents “ Total Co
Slide 32: Q&A
Q&A www.Windtreetx.com se a6 WINDTREE
Slide 33: Slide 33
Slide 34: Acute Heart Failure — Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need Patient Management Goals Current Treatment Options * Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: Relieve pulmonary Heart rhythm disturbance
Slide 35: Cardiogenic Shock Treatment
Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Regulatory Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway Ot _©©— Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of dr
Slide 36: Primary Endpoint Achieved
Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume Istaroxime 0.5 yg/kg/min vs. placebo *pvalue =0.029 2aheurs ——«@howre Bacaline =-4- Praceto-Cohot 1 ee istzonine oS yyt9me e Infusion period Semine «ham Mhoum—Doum &R nam race - Hesse 0S porgiin Cy WINDTREE Ele’ Stroke Vo
Slide 37: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve
Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve e 0.5 g/kg/min vs. placebo Istaroxime 1.0 ug/kg/min vs. placebo 1 z Gare Be * Brraues £0.006 E Blood == * is a? Pressure 3° ze 4 (SBP) ae i: 4 i: a 5 a Zl insion period eos eon Then Hos Aeon Tatoos Tomine Shoes G
Slide 38: Heart Rate Decreased and No Increases in Cardiac Troponins
Heart Rate Decreased and No Increases in Cardiac Troponins se w@ WINDTREE ‘Change in lear tate (om) Istaroxime 0.5 yg/kg/min vs. placebo *pvalue=0.014 == Pieeto-Cohen = tawcine sultan eTnT-0to 24 hours —eo5ugKomn —e—1ougngmn ~~» —Placere Cardiac TnT (Myocardial Damage) ‘ange intent tate opm) Istarox
Slide 39: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring 120% 100% 80% | 60% 40% 20% oo% Clinically Significant Arrhythmias celine sPiaebo- Cohort 25.0% 75% Baeaine stains 05 ugKglmn Placebo -Conot2 20% em 1258 100% 100% 100% | & . | oo L — ay 1 ntusion) Day 2 ‘Day 1 tus) Day 2 ‘mistxcrime 10 ugK9m
Slide 40: Adverse Events
Adverse Events Pooled placebo _‘"staroxime 0.5 Istaroxime 1.0 (a9) mgi/Kgimin mgiKgimin (0=41) (n=40) All adverse events: 23 (59.0%) 31 (75.6%) 33 (82.5%). eaettgs even lees 126%) : 4(10.0%) Serious adverse events 2 (5.1%) 2(4.9%) 6 (15.0%) Cardiac death - - 1 (2.5%) Cardiogenic shock z z 1 (25%) Ca
Slide 41: Rostafuroxin — A Potential New Treatment for Resistant Hypertension
Rostafuroxin — A Potential New Treat for Resistant Hypertension (RHTN) Rostafuroxin There have been seven clinical studies of rostafuroxin in treatment naive hypertension (patients without any treatment), including 4 Phase 2 studies which examined the antihypertensive effect, safety and tolerability
Slide 42: Large Market with Significant Unmet Need
Large Market with Significant Unmet Need » Treatment resistant hypertension — An estimated 10% to 20% of hypertensive patients have resistant hypertension, defined as having controlled or uncontrolled blood pressure with the use of = 3 medications that includes a diuretic* » Effective hypertension t